The number of employees laid off dropped year over year during the first quarter. BioSpace recaps the five largest layoffs, ...

Health and Human Services employees aren’t the only ones out of work. Thousands of private-sector biopharma professionals ...

As the biopharma industry grapples with the uncertain macro environment brought on by the new administration, CEOs, ...

Experts express concern that last week's unprecedented FDA layoffs will trigger a little-known mechanism that could result in ...

According to analysts at Jefferies, legislation such as the newly proposed bills that aim to streamline regulatory processes ...

Novartis plans to build seven new facilities in the U.S., touting the creation of up to 1,000 new jobs at the company. The ...

Analysts at William Blair expect drug developers will continue to perform “at least some animal testing” on their ...

Biotech companies are already seeing regulatory delays and plenty of uncertainty after around 3,500 FDA employees were cut by ...

The threat of tariffs has put the pharma industry through the wringer this week. On Wednesday, a week after instituting widespread tariffs and a day after promising that “major” tariffs were headed ...

According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.

In this episode presented by DIA, BioSpace's head of insights Lori Ellis discusses the underrepresentation of women in clinical trials with Martin Hodosi, partner at Kearney and Melissa Laitner, ...

To beef up its case for tanruprubart, Annexon also announced on Wednesday that a real-world study of the drug likewise showed a “rapid increase in muscle strength” versus current standards of care in ...